We observed a significant increase in AURKA expression in CRPC (n = 35) compared to primary localised PC (n = 59) and benign (n = 28) samples (p = <0.0001 and p = <0.0001, respectively) with a significant increase between benign and localise PC samples (p = 0.0130) (Fig. 1c) suggesting a role of Aurora A in prostate cancer progression. Here, AURKA is linked to prostate carcinoma.